Prevalence and Description of Patients With Netherton Syndrome in France

Background Netherton syndrome (NS; recently designated SPINK5‐sEDD) is an autosomal recessive systemic epidermal differentiation disorder, which manifests at birth or shortly thereafter and is caused by loss‐of‐function mutations in the serine protease inhibitor of Kazal type 5 gene. Objectives The current study aims to provide data on the prevalence, demographics, mortality and clinical characteristics of individuals with NS in France. Methods This is a non‐interventional nationwide multicenter cross‐sectional study based on the ‘banque nationale de données maladies rares’ (BNDMR) database, that collects data for all patients attending rare disease referral centres. All patients diagnosed with NS who have received care at a referral centre in France were included in this study, unless they did not consent to their data being used for research purposes. Results On 1 January 2025, 111 patients were included in the database. Among the 111 patients, 64 (57.7%) were female, and 47 (42.3%) were male. The mean age by 1 January 2025 was 25.2 years. Of the 111 patients, nine were deceased by the time of data extraction. Based on the French population size at the same time point, a prevalence of 1.41 per million persons (95% CI: 1.15–1.73) is estimated. The majority of patients (88.0%) experienced their first symptoms within the first 28 days of life (newborn period). The mean delay between symptom onset and diagnosis was calculable for 63 patients (56.8%). Among them, 49.2% were diagnosed in the same month as symptom onset, 22.2% within the first year and 28.6% after more than 1 year. Limitations Patients with milder or undiagnosed disease, those who objected to the secondary use of their data for research and those who were never referred to an expert centre were not captured, potentially limiting the representativeness of the study population. In addition, missing data—particularly regarding diagnostic delay and neonatal characteristics—limited the completeness of some analyses. Conclusions This study leads to a prevalence of NS of 1.41 per million persons.

Authors

Institutions

Publication Details

Journal
JEADV Clinical Practice
Published
2026-11-18
DOI
https://doi.org/10.1002/jvc2.70499
Primary Topic
Skin and Cellular Biology Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prevalence and Description of Patients With Netherton Syndrome in France

Stephane Bouée, Julien Chollet, Najean Marie, Jannot Anne‐Sophie et al.
JEADV Clinical Practice
Skin and Cellular Biology Research
article

Prevalence and Description of Patients With Netherton Syndrome in France

Stephane Bouée, Julien Chollet, Najean Marie, Jannot Anne‐Sophie, Faujour Corentin, Bodemer Christine, Droitcourt Catherine, Unigwe Ikenna
article en

Abstract

Background Netherton syndrome (NS; recently designated SPINK5‐sEDD) is an autosomal recessive systemic epidermal differentiation disorder, which manifests at birth or shortly thereafter and is caused by loss‐of‐function mutations in the serine protease inhibitor of Kazal type 5 gene. Objectives The current study aims to provide data on the prevalence, demographics, mortality and clinical characteristics of individuals with NS in France. Methods This is a non‐interventional nationwide multicenter cross‐sectional study based on the ‘banque nationale de données maladies rares’ (BNDMR) database, that collects data for all patients attending rare disease referral centres. All patients diagnosed with NS who have received care at a referral centre in France were included in this study, unless they did not consent to their data being used for research purposes. Results On 1 January 2025, 111 patients were included in the database. Among the 111 patients, 64 (57.7%) were female, and 47 (42.3%) were male. The mean age by 1 January 2025 was 25.2 years. Of the 111 patients, nine were deceased by the time of data extraction. Based on the French population size at the same time point, a prevalence of 1.41 per million persons (95% CI: 1.15–1.73) is estimated. The majority of patients (88.0%) experienced their first symptoms within the first 28 days of life (newborn period). The mean delay between symptom onset and diagnosis was calculable for 63 patients (56.8%). Among them, 49.2% were diagnosed in the same month as symptom onset, 22.2% within the first year and 28.6% after more than 1 year. Limitations Patients with milder or undiagnosed disease, those who objected to the secondary use of their data for research and those who were never referred to an expert centre were not captured, potentially limiting the representativeness of the study population. In addition, missing data—particularly regarding diagnostic delay and neonatal characteristics—limited the completeness of some analyses. Conclusions This study leads to a prevalence of NS of 1.41 per million persons.

JEADV Clinical Practice
Hôpital Necker-Enfants Malades (FR), Inserm (FR), École des Hautes Études en Santé Publique (FR), Université Paris Cité (FR), Cemka-Eval (France) (FR), Sorbonne Paris Cité (FR), Assistance Publique – Hôpitaux de Paris (FR), Institut de Recherche en Santé, Environnement et Travail (FR), Boehringer Ingelheim (France) (FR), Centre Hospitalier Universitaire de Rennes (FR), Boehringer Ingelheim (United States) (US), Heka : Méthodes basées sur les données et modèles en santé pour l'acquisition de connaissances (FR), Université de Rennes (FR)
Boehringer Ingelheim
Good health and well-being
Skin and Cellular Biology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon